Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 8.33
INSM's Cash to Debt is ranked higher than
68% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. INSM: 8.33 )
INSM' s 10-Year Cash to Debt Range
Min: 0.86   Max: No Debt
Current: 8.33

F-Score: 3
Z-Score: 8.68
M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -478.39
INSM's Operating margin (%) is ranked higher than
61% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. INSM: -478.39 )
INSM' s 10-Year Operating margin (%) Range
Min: -135891.67   Max: -83.62
Current: -478.39

-135891.67
-83.62
Net-margin (%) -487.59
INSM's Net-margin (%) is ranked higher than
60% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. INSM: -487.59 )
INSM' s 10-Year Net-margin (%) Range
Min: -133103.33   Max: 1140.94
Current: -487.59

-133103.33
1140.94
ROE (%) -52.31
INSM's ROE (%) is ranked higher than
68% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. INSM: -52.31 )
INSM' s 10-Year ROE (%) Range
Min: -460.81   Max: 195.47
Current: -52.31

-460.81
195.47
ROA (%) -42.31
INSM's ROA (%) is ranked higher than
67% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. INSM: -42.31 )
INSM' s 10-Year ROA (%) Range
Min: -228.14   Max: 180.06
Current: -42.31

-228.14
180.06
ROC (Joel Greenblatt) (%) -2427.92
INSM's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. INSM: -2427.92 )
INSM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -720550   Max: -1468.6
Current: -2427.92

-720550
-1468.6
Revenue Growth (%) -14.10
INSM's Revenue Growth (%) is ranked higher than
70% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. INSM: -14.10 )
INSM' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 217.5
Current: -14.1

-100
217.5
EBITDA Growth (%) 48.80
INSM's EBITDA Growth (%) is ranked higher than
97% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. INSM: 48.80 )
INSM' s 10-Year EBITDA Growth (%) Range
Min: -59.4   Max: 48.8
Current: 48.8

-59.4
48.8
EPS Growth (%) 48.40
INSM's EPS Growth (%) is ranked higher than
97% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INSM: 48.40 )
INSM' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 48.4
Current: 48.4

-59.5
48.4
» INSM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

INSM Guru Trades in Q4 2013

Steven Cohen 492,957 sh (+35.95%)
» More
Q1 2014

INSM Guru Trades in Q1 2014

John Burbank 10,328 sh (New)
Steven Cohen 80,000 sh (unchged)
Steven Cohen 203,000 sh (-58.82%)
» More
Q2 2014

INSM Guru Trades in Q2 2014

Jim Simons 48,587 sh (New)
Steven Cohen 651,687 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

INSM Guru Trades in Q3 2014

Steven Cohen 2,569,636 sh (+294.31%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$12.1 - $19.73 $ 14.24-3%0
John Burbank 2014-03-31 New Buy0.01%$15.905 - $21.54 $ 14.24-25%10328
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.81
INSM's P/B is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. INSM: 2.81 )
INSM' s 10-Year P/B Range
Min: 0.45   Max: 105
Current: 2.81

0.45
105
EV-to-EBIT -7.01
INSM's EV-to-EBIT is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSM: -7.01 )
INSM' s 10-Year EV-to-EBIT Range
Min: -18.6   Max: 28
Current: -7.01

-18.6
28
Shiller P/E 38.87
INSM's Shiller P/E is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSM: 38.87 )
INSM' s 10-Year Shiller P/E Range
Min: 22   Max: 45.13
Current: 38.87

22
45.13
Current Ratio 8.03
INSM's Current Ratio is ranked higher than
83% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. INSM: 8.03 )
INSM' s 10-Year Current Ratio Range
Min: 0.53   Max: 54.49
Current: 8.03

0.53
54.49
Quick Ratio 8.03
INSM's Quick Ratio is ranked higher than
84% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. INSM: 8.03 )
INSM' s 10-Year Quick Ratio Range
Min: 0.53   Max: 54.49
Current: 8.03

0.53
54.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.26
INSM's Price/Net Cash is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. INSM: 4.26 )
INSM' s 10-Year Price/Net Cash Range
Min: 0.57   Max: 197.5
Current: 4.26

0.57
197.5
Price/Net Current Asset Value 4.26
INSM's Price/Net Current Asset Value is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. INSM: 4.26 )
INSM' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 940
Current: 4.26

0.54
940
Price/Tangible Book 3.96
INSM's Price/Tangible Book is ranked higher than
85% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. INSM: 3.96 )
INSM' s 10-Year Price/Tangible Book Range
Min: 0.51   Max: 90
Current: 3.96

0.51
90
Earnings Yield (Greenblatt) -14.30
INSM's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. INSM: -14.30 )
INSM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 43451.1
Current: -14.3

3.6
43451.1
Forward Rate of Return (Yacktman) -4.06
INSM's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. INSM: -4.06 )
INSM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -176.2   Max: -1.7
Current: -4.06

-176.2
-1.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM8N.Germany
Insmed, Inc. was incorporated in the Commonwealth of Virginia on November 29, 1999. The Company is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. It is currently conducting a phase 2 clinical trial in the United States and Canada of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria. In 2013, it concluded a phase 3 clinical trial in Europe and Canada of ARIKAYCE in cystic fibrosis patients who have lung infections caused by Pseudomonas aeruginosa. The Company intends to develop ARIKAYCE to broaden the non-tuberculous mycobacteria indication and for additional indications beyond Pseudomonas in cystic fibrosis and non-tuberculous mycobacteria. ARIKAYCE received orphan drug status in the US and Europe for the treatment of non-tuberculous mycobacteria. The Company's registered trademarks are Insmed, ARIKACE, ARIKAYCE, and IPLEX. Its second proprietary compound is IPLEX, which is IGF-1, with its natural binding protein, IGFBP-3. IPLEX is no longer a development priority for the Company. Its competitors include pharmaceutical and biotechnology companies that have approved therapies or therapies in development for the treatment of chronic lung infections.
» More Articles for INSM

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CEO Buys Highlight: TPGI, INSM, EQU, FCEL Jan 13 2013 
INSMED Inc -- A Merger Ruined its Net-Net Status Feb 02 2011 
Insmed Inc. Reports Operating Results (10-Q) Nov 03 2010 
Insmed Inc. Reports Operating Results (10-Q) Aug 04 2010 
Insmed Inc. Reports Operating Results (10-Q) May 06 2010 
Jim Simons Low P/E Stocks: Insmed Inc., Paragon Shipping Inc., The Student Loan Corp., Hellenic Tele Apr 28 2010 
frankvis note on INSM Feb 08 2010 
8 Cheap Stocks Below Net Net Working Capital Dec 14 2009 
Insmed Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
INSMED INC Financials Nov 14 2014
10-Q for Insmed, Inc. Nov 09 2014
Insmed posts 3Q loss Nov 06 2014
Insmed posts 3Q loss Nov 06 2014
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 06 2014
Insmed Reports Third Quarter 2014 Financial Results Nov 06 2014
INSMED INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Insmed Reports Third Quarter 2014 Financial Results Nov 06 2014
Q3 2014 Insmed Inc Earnings Release - Before Market Open Nov 06 2014
Insmed to Host Third Quarter 2014 Financial Results Conference Call on Thursday, November 6, 2014 Oct 31 2014
Insmed to Host Third Quarter 2014 Financial Results Conference Call on Thursday, November 6, 2014 Oct 31 2014
Insmed to Participate in Leerink Partners’ Rare Disease Roundtable Sep 24 2014
Insmed to Present at the Rodman & Renshaw Annual Global Investment Conference Sep 05 2014
Insmed Announces Multiple Clinical and Scientific Presentations at European Respiratory Society's... Sep 03 2014
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2014
Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares Aug 18 2014
Insmed Incorporated (INSM) in Focus: Stock Up 10.9% Aug 14 2014
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
Insmed Announces Pricing of Public Offering of Common Stock Aug 12 2014
Insmed Announces Proposed Public Offering of Common Stock Aug 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK